Bladder cancer treatment without bladder removal
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a combination of two drugs can treat bladder cancer without needing to remove the bladder. It is for people whose cancer has not spread beyond the bladder and who prefer to avoid surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with bladder cancer that started in the bladder lining.
- Your cancer is at a stage where it has grown into the bladder muscle but has not spread to lymph nodes or other organs.
- Your tumor has a certain protein marker called HER2 at a level of 2+ or higher.
- You have decided not to have your bladder removed (radical cystectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial tests a combination of two drugs, disitamab vedotin and ivonescimab, for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy with cisplatin. The goal is to see if this treatment is safe and effective before surgery.
This study tests a new type of targeted therapy combined with immunotherapy against standard immunotherapy plus chemotherapy for people with a very high-risk, non-invasive bladder cancer that cannot be fully removed by surgery. The goal is to see if the new combination is more effective and safe.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.